

Special Issue

Potential Therapeutic Target for Atherosclerosis

Message from the Guest Editor

Atherosclerosis, the main underlying cause of cardiovascular disease (CVD), is characterized by sustained inflammation and failed inflammation resolution. Despite the great advances in pharmaceutical therapy, CVD remains the leading cause of death worldwide. A deeper understanding of the mechanisms that promote atherosclerotic lesion onset and progression may identify novel therapeutic targets for the prevention and treatment of the disease. The aim of the present Special Issue is to attract high-quality articles that focus on potential innovative therapeutic strategies for the immune, cellular, and molecular mechanisms of atherosclerosis. We welcome opinions, brief reports, communications, and research articles, as well as reviews.

Guest Editor

Dr. Catherine Martel

1. Montreal Heart Institute, Montréal, QC H1T1C8, Canada
2. Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada

Deadline for manuscript submissions

closed (30 September 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/116927

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)